Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882895 · ClinicalTrials.gov registry record · Phase 2
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, Non-Hodgkin, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00882895 is a Phase 2 study of Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 18 participants, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00882895, a Phase 2 study of Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study testing a new approach to treating high-risk non-Hodgkin's lymphoma consisting of an autologous hematopoietic (blood) stem cell transplant (using a patient's own hematopoietic cells) followed by a non-myeloablative allogeneic transplantation (transplant from another individual). The investigators hypothesize that the addition of the second non-myeloablative transplant will improve the chances for long-term control of lymphoma.
Conditions Studied
Interventions
- DRUG Tacrolimus
- PROCEDURE Stem cell infusion
- PROCEDURE TLI
- DRUG Anti-thymocyte globulin
- DRUG Solumedrol
Study Locations (1)
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-05-05 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882895
The ClinicalTrials.gov registry entry for NCT00882895 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (95% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 5 interventions - of which Tacrolimus is the first listed.
NCT00882895 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00882895 about?
NCT00882895 is a clinical study titled "Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma". This is a research study testing a new approach to treating high-risk non-Hodgkin's lymphoma consisting of an autologous hematopoietic (blood) stem cell transplant (using a patient's own hematopoietic cells) followed by a non-myeloablative allogeneic transplantation (transplant from another individu...
What is the current status of trial NCT00882895?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2009-05-05. Estimated completion is 2028-06-01.
What conditions does trial NCT00882895 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT00882895?
The interventions under investigation include: Tacrolimus (DRUG), Stem cell infusion (PROCEDURE), TLI (PROCEDURE), Anti-thymocyte globulin (DRUG), Solumedrol (DRUG).
Who is sponsoring clinical trial NCT00882895?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00882895 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
ACTIVE NOT RECRUITING · Phase 2
-
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.